ORIGINAL ARTICLE

Corneal-Wavefront guided transepithelial photorefractive keratectomy after corneal collagen cross linking in keratoconus

Massimo Camellin a,⁎, Jacopo Maria Guidotti b, Samuel Arba Mosquera c

a SEKAL Rovigo Microsurgery Centre, Rovigo, Italy
b Studio Medico Guidotti, Bologna, Italy
c SCHWIND eye-tech-solutions, Kleinostheim, Germany

Received 10 November 2015; accepted 3 February 2016
Available online 21 March 2016

KEYWORDS
Transepithelial photorefractive keratectomy; Corneal-Wavefront guided; Corneal collagen cross linking; Keratoconus; Refracto-therapeutic

Abstract

Purpose: To evaluate the efficacy and safety of Corneal-Wavefront guided transepithelial photorefractive keratectomy (TransPRK) after corneal collagen cross linking (CXL) in keratoconic patients.
Methods: In this retrospective, non-comparative, consecutive case series, 39 keratoconic eyes underwent Corneal-Wavefront guided TransPRK for the correction of aberrations at least 4 months after conventional CXL at SEKAL Rovigo Microsurgery Centre, Rovigo, Italy. Two eyes (5%) underwent a secondary laser retreatment for the improvement of post-operative visual acuity and were not included in this retrospective analysis. The mean age of the patients was 35 ± 12 years (19–64 years) at the time of the surgery. Keratron-Scout (Optikon) topographer was used for diagnostic tests and a flying-spot laser (AMARIS; SCHWIND eye-tech-solutions) was used for the refractive surgery. Complete ophthalmic examinations were performed before and after the surgery (4–36 months postoperatively with a mean follow up time of 10 ± 8 months).
Results: Preoperatively, eyes showed irregular astigmatism up to 8D. At last postoperative follow-up, 21 eyes (57%) had UDVA better than 20/40, and six eyes (16%) had UDVA of 20/20. Twenty-three eyes (62%) were within 1.50D of attempted correction in spherical equivalent (mean deviation from target was +1.09 ± 2.36D, range =−2.50 to +7.38D). No eye lost 2 Snellen lines of CDVA, and 15 eyes (41%) had an increase of more than 2 lines.
Conclusions: Corneal-Wavefront guided transepithelial PRK ablation profiles after conventional CXL yields to good visual, optical, and refractive results. These treatments are safe and efficacious for the correction of refracto-therapeutic problems in keratoconic patients.

© 2016 Spanish General Council of Optometry. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

⁎ Corresponding author at: SEKAL Rovigo Microsurgery Centre, Rovigo, Italy.
E-mail address: massimo.camellin@sekal.it (M. Camellin).

http://dx.doi.org/10.1016/j.optom.2016.02.001
1888-4296/© 2016 Spanish General Council of Optometry. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

Refracto-therapeutic surgery with excimer laser has evolved rapidly in the last decade to correct severe, disabling irregular astigmatism in corneal pathologies. In one of the earliest attempts to treat irregular cornea using a custom excimer laser ablations, visual symptoms were reported to resolve or decrease with both manual adjustment of laser beam placement and contoured ablation patterns. The initial procedures were based on Photo refractive keratectomy (PRK) and reported limited effectiveness. In more recent reports, Alpins and Stamatelatos reported that the incorporation of the corneal astigmatism data into the applied treatment parameters may improve visual and total astigmatism results in eyes with forme fruste and mild keratoconus. The correction of classical ametropias (myopia and astigmatism) in keratoconus using transepithelial PRK has been reported as less effective and less predictable than conventional PRK for naturally occurring myopia and astigmatism. Refracto-therapeutic ablations have evolved to the more sophisticated topography-guided and corneal wavefront-guided customized corneal ablations for irregular corneal astigmatism in keratoconus. In a latest pilot study, Shaheen et al. evaluated the visual, refractive, corneal topographic, and aberrometric changes after wavefront-guided Laser-in situ-keratomileusis (LASIK) or PRK using a high-resolution aberrometer to calculate the treatment for aberrated eyes. They differentiated the patients in three groups: keratoconus post-CXL group including 11 keratoconic eyes (10 patients), post-LASIK group including 5 eyes (5 patients) with previous decentered LASIK treatments, and post-RK group including 4 eyes (3 patients) with previous radial keratotomy. They reported an improvement in uncorrected and corrected distance visual acuity (UDVA and CDVA respectively) associated with a reduction in the spherical equivalent in all three groups, but was only statistically significant in the keratoconus post-CXL and post-LASIK groups (P < .04). Similarly improvements in contrast sensitivity were observed in all three groups, but they were only statistically significant in the keratoconus post-CXL and post-LASIK groups (P < .04).

Several combinations of therapeutic and refractive surgery approaches have been advocated. A 2-step sequential approach was proposed in the form of CXL + customized PRK. This is in comparison to the simultaneous procedures done in the form of same day phototherapeutic keratectomy (PTK) + customized PRK followed by a CXL procedure to control the progression of keratoconus. Another
which technique

Topographers measure the anterior corneal surface i.e.

It is worth noticing that there are a significant num-

In an unfavourable case, the internal stromal irregular-

It is worth noticing that there are a significant num-

The first 39 eyes (37 patients) that presented with kerato-

Methods

Patient population and examinations

The first 39 eyes (37 patients) that presented with kerato-

by refractive treatments for correcting refracto-therapeutic

A minimum follow up of at least four months after

Treatment plan

The following sequence was followed during the complete

Surgical technique and laser system

For corneal and conjunctival anaesthesia, two drops of

by refractive treatments for correcting refracto-therapeutic

A minimum follow up of at least four months after

Baseline examinations included measurement of UDVA,

The following sequence was followed during the complete

Surgical technique and laser system

For corneal and conjunctival anaesthesia, two drops of

by refractive treatments for correcting refracto-therapeutic

A minimum follow up of at least four months after

Baseline examinations included measurement of UDVA,

The following sequence was followed during the complete

Surgical technique and laser system

For corneal and conjunctival anaesthesia, two drops of
epithelial thickness profile \( 55 \mu m \) (in the centre and 65 \( \mu m \) at 4 \( mm \) radial distance) was ablated without using any masking fluid. The epithelial profile was based on normal epithelium, but also on refractive neutrality of an epithelial ablation.\(^{21,22} \) Considering the refractive indices of air \((1.000)\), epithelium \((1.401)\), stroma \((1.376)\), and aqueous humour \((1.336)\) and applying thin and thick lens equations, refractive neutrality after removing 55 \( \mu m \) of epithelium or stroma, will be achieved by removing 61 \( \mu m \) of peripheral tissue at 4 \( mm \) of radial distance. So the refractive power of the normal epithelium also equates to 0.5D, which is compensated by the normal epithelial profile used here.

Treatment was planned to target complete coma aberrations and using a partial refraction in sphere and cylinder in order not to exceed the stromal ablation beyond 55 \( \mu m \) ablation depth \((110 \mu m \) overall ablation). Although the treatments were generally planned to target complete spherical and 50% astigmatic correction such that the planned ablation depth do not exceed the stromal ablation depth more than 55 \( \mu m \) (excessively not to reduce the strength of the cornea reinforced by the CXL therapy), in case the ablation depth increased beyond 55 \( \mu m \) during treatment planning, sphere and cylinder refraction was individually manipulated to respect the upper limit in ablation depth. Fifty-five micrometres were used as the maximum level of ablation depth based on empirical observations, independent from the level of residual stromal bed. No progression of ectasia was observed at this ablation depth. No additional nomogram was used to compensate the effect of the CXL treatments in the patients since the primary outcome in our cohort was CDVA and not UDVA, aimed at improving the patient’s vision with the use of conventional correction modalities like spectacles and increasing tolerance to contact lenses.

The mean optical zone was 6.1 \( \pm \) 0.3 \( mm \) \((5.5–6.7 \( mm \)) with a variable transition size automatically provided by the laser based on the planned refractive correction \((6.8 \pm 0.5 \( mm \), range 6.2–8.1 \( mm \))\). This implies that with the central ablation depth set at the upper limit of 55 \( \mu m \), in a 6.7 \( mm \) optical zone (upper limit), \(-3.5D \) of astigmatism could be treated in the most myopic meridian.

The ablation was performed with the AMARIS excimer laser using real ablative spot shape \((volume)\) locally considered through a self-constructing algorithm. A randomized flying-spot ablation pattern was applied to minimize the thermal load of the treatment.\(^{23} \) The difference in the photobleative rate between stroma and epithelial tissue \(^{24} \) (\(~20% \) higher in epithelium) was partly compensated by the laser system. A single ablation volume was discretized into laser pulses sorted spatially and temporally in a pseudo-random fashion. A pseudo-segmentalization of the Corneal-Wavefront guided refractive correction profile and the epithelial thickness profile components was realized, but both components elapsed without breaks. This meant that in a counterintuitive way, the refractive correction was applied first (actually, at least in part, at the epithelial tissue), and the epithelial profile at the end (just to complete the epithelium removal in areas including optical zone (OZ) and transition zone (TZ) where it has not been completely removed yet). A contact lens \((Proclear \ 8.6 \ - \ 14.2 \ - \ 0 \ - \ Cooper \ Vision \ - \ Scottsdale \ - \ USA)\) was applied at the end of surgery.

### Postoperative treatment

Prior to epithelial healing, eye drops Ribomicin\(^ {(Gen- tamycin \ 0–3% \ Farmigea \ - \ Pisa \ - \ Italy)} \) and voltaren Ofta \((Diclofenac \ sodium \ 0.1% \ - \ Novartis \ Farma \ - \ Varese)\) were applied. Bandage contact lens was applied for 4–5 days until complete healing of the epithelial defect. After epithelial healing, preservative free artificial tear eye drops were applied along with Visucloten\(^ {(Clobetazone \ 0.1% \ - \ Visu- farma \ - \ Rome \ - \ Italy)}\) bid for 30 days.

### Efficacy

The number of eyes with postoperative UDVA in scale from 20/20 to 20/63 was analyzed.

### Safety

The differences in postoperative CDVA compared to the preoperative baseline was analyzed for each eye.

### Predictability

Scattergrams were plotted for the achieved correction versus the attempted correction (both at the corneal plane, where the ablation procedures are performed). We analyzed the slope and the intercept of the correlations along with the statistical significance of the correlations based on the Student’s \( T \)-tests and the coefficient of determination \((r^2)\). The significance of the correlations was evaluated considering a metric distributed approximately as \( t \) with \( N – 2 \) degrees of freedom, where \( N \) is the size of the sample.

### Refractive outcome

The average of the refractive outcomes in all the treatments was analyzed. Additionally, in order to evaluate the distribution in the treated population post-operatively, the total number of treatments was stratified according to the post-operative spherical equivalent and refractive astigmatism.

### Changes in corneal wavefront aberration at 5 mm analysis diameter

The mean values and differences of the Zernike coefficients (with the Zernike expansion up to the seventh order) were analyzed postoperatively compared to the preoperative baseline for each eye.

### Statistical analysis

The statistical significance of the postoperative status was compared to the preoperative baseline using paired student’s \( T \)-tests and intergroup differences using unpaired student’s \( T \)-tests. The level of statistical significance was taken as \( P < .05 \).
Table 1 Preoperative data.

<table>
<thead>
<tr>
<th>Preoperative</th>
<th>After CXL</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eyes (n)</td>
<td>37</td>
<td></td>
</tr>
<tr>
<td>Age (yo)</td>
<td>35 ± 12 (19 to 64)</td>
<td></td>
</tr>
<tr>
<td>UDVA (logMAR)</td>
<td>+1.0 ± 0.6 (+0.1 to +2.0)</td>
<td></td>
</tr>
<tr>
<td>SEq (D)</td>
<td>−4.17 ± 3.93 (−13.00 to +0.38)</td>
<td></td>
</tr>
<tr>
<td>Ast (D)</td>
<td>3.43 ± 1.79 (0.25–8.00)</td>
<td></td>
</tr>
<tr>
<td>CDVA (logMAR)</td>
<td>+0.4 ± 0.2 (+0.1 to +1.0)</td>
<td></td>
</tr>
<tr>
<td>CW Coma @ 5.5 mm</td>
<td>1.87 ± 0.91 (0.20–4.48)</td>
<td></td>
</tr>
<tr>
<td>(μm)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CW SphAb @ 5.5 mm</td>
<td>+0.02 ± 0.37 (−1.16 to +0.63)</td>
<td></td>
</tr>
<tr>
<td>(μm)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CW RMSHO @ 5.5 mm</td>
<td>3.26 ± 1.28 (0.73–6.16)</td>
<td></td>
</tr>
<tr>
<td>(μm)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Follow-up time

Mean follow-up time was 10 ± 8 months (4–36 months). In our cohort, 22 eyes, 9 eyes, 5 eyes and 1 eye completed a follow-up of 4 months, 12 months, 24 months and 36 months, respectively.

Efficacy

At the last follow-up visit, UDVA of 20/32 or better was achieved in 46% (17 eyes), and 20/50 or better in 68% (25 eyes) of the eyes (paired t-test P < .0001) (Fig. 1), with a mean UDVA of 0.4 ± 0.4 logMAR (0.0–2.0 logMAR) (Table 2).

Safety

At the last follow-up visit, 41% of eyes (15 eyes) gained two or more Snellen lines of CDVA (paired t-test P < .0001) (Fig. 2). The mean gain of lines was +1.8 ± 1.6 lines (−1.2 to +6 lines), with mean CDVA of 0.2 ± 0.2 logMAR (0.0–1.0 logMAR) (Table 2). The mean hase score at the last follow up was 0.1 ± 0.2. Haze was graded according to the fantes scale elucidated in Ref. 25.

Predictability

Achieved defocus correction showed a linear correlation with attempted defocus correction (slope = 0.8178, intercept = −1.2213D and r² = 0.1081) (Fig. 3).

Refractive outcome

At the last follow-up visit, mean residual defocus was −2.38 ± 3.29D (−10.00 to +3.00D), whereas the mean deviation from target defocus was +1.09 ± 2.36D (−2.50 to +7.38D) (paired t-test P < .001). The mean residual astigmatism was 2.34 ± 1.81D (0.00–6.25D), whereas the mean deviation from target astigmatism was 0.64 ± 1.85D (−3.00 to +6.00D) (paired t-test P < .0001) (Figs. 4 and 5).

Changes in corneal wavefront aberration at 5 mm analysis diameter

At last follow-up visit, mean residual coma was 1.08 ± 0.80 μm (0.03–4.29 μm) (paired t-test P < .0001). The mean residual spherical aberration was −0.08 ± 0.36 μm (−1.12 to 0.65 μm) (paired t-test P < .05); whereas mean residual RMS of the HOA was 2.83 ± 1.50 μm (0.65–7.87 μm) (paired t-test P < .05). Postoperative aberrations correlated well with preoperative aberrations, with slopes of 0.27, 0.65, and 0.67 for coma, spherical aberration, and RMS of the HOA, respectively, with intercepts of 0.57 μm, −0.10 μm, and 0.63 μm for coma, spherical aberration, and RMS of the HOA, respectively (Figs. 6 and 7). The postoperative aberration reduced by an average −33 ± 81% for coma, and −25 ± 32% for the RMS of the HOA.

Results

Preoperative assessment

Tables 1 and 2 present the preoperative and post-operative data respectively. Preoperatively, mean manifest defocus refraction was −4.17 ± 3.93D (−13.00 to +0.38D), with a mean manifest astigmatism magnitude of 3.43 ± 1.79D (0.25–8.00D). The achieved mean CDVA was +0.4 ± 0.2 logMAR (+0.1 to +1.0 logMAR), and root-mean-square (RMS) high-order-aberration (HOA) of the corneal wavefront (CW) was 3.26 ± 1.28 μm (0.73–6.16 μm, at 5 mm analysis diameter). All patients were within 2–3 stage of Keratoconus assessed according to Ref. 15.

Adverse events

Neither adverse events nor complications were observed intra- or postoperatively. Two eyes (5%) underwent a secondary laser retreatment for the improvement of postoperative visual acuity. These results are not reported here.

Table 2 Postoperative data at the last follow-up visit.

<table>
<thead>
<tr>
<th>Postoperative</th>
<th>After CXL and transepithelial refracto-therapeutic procedure</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Follow-up (m)</td>
<td>10 ± 8 (4–36)</td>
<td>&lt;</td>
</tr>
<tr>
<td>UDVA (logMAR)</td>
<td>0.4 ± 0.4 (0.0–2.0)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>SEq (D)</td>
<td>−2.38 ± 3.29 (−10.00 to +3.00)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Ast (D)</td>
<td>2.34 ± 1.81 (0.00–6.25)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>CDVA (logMAR)</td>
<td>0.2 ± 0.2 (0.0–1.0)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>CW Coma @ 5.5 mm (μm)</td>
<td>1.08 ± 0.80</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>CW SphAb @ 5.5 mm (μm)</td>
<td>−0.08 ± 0.36 (−1.12 to +0.65)</td>
<td>&lt;.05</td>
</tr>
<tr>
<td>CW RMSHO @ 5.5 mm (μm)</td>
<td>2.83 ± 1.50 (0.65–7.87)</td>
<td>&lt;.05</td>
</tr>
</tbody>
</table>
Discussion

The aim of this study was to evaluate the efficacy and safety of reversed single-step Corneal-Wavefront guided transepithelial PRK treatments in keratoconic patients after CXL. Kanellopoulos also discussed and applied the possibility of reversed transepithelial PRK (although in a manual fashion) to his last series of patients as reported during ESCR 2013 in Amsterdam.

The reversed transepithelial approach has at least three advantages in our understanding; first, the more regular epithelial surface is ablated with the complex ablation profile instead of the comparatively irregular stroma. This means that the regularity of epithelium is carried down to the stroma with a fine laser ablation profile. Second, the ablation profile calculated based on the diagnosis of essentially the corneal epithelial surface is applied directly on to the epithelium instead of the stroma. This could impart a higher coherence between the diagnosis and refractive procedure. Third, since the cooperation of the patients is likely better at the beginning of the treatment, leaving the very simple epithelial profile for the last ablation seconds reduces the impact of suboptimal centration (although with very fast treatments this may eventually be irrelevant).

Topography-guided transepithelial PRK is commonly considered a more popular choice for the treatment of
Figure 3  Attempted versus achieved spherical equivalent refraction (SE) in keratoconic patients who underwent corneal collagen cross linking followed by Corneal-Wavefront guided transepithelial photorefractive keratectomy (TransPRK). Achieved SE correction showed a linear correlation with attempted SE correction (slope = 0.8178, intercept = -1.2213D and $r^2 = 0.1081$) (Fig. 3), however with a wide distribution.

keratoconus instead of the wavefront guided transepithelial PRK. However, we used the corneal wavefront guided ablation profiles, which have the same origins (topographic measurement) as topography-guided treatments but base upon the optical effects of the topography of the cornea instead of the elevation values of the cornea. We have reported refractive stability and optical benefits using the wavefront guided profiles in normal refractive procedures and therapeutic procedures in the past. Furthermore, the calculation of corneal asphericity as a 3-D fit renders more accurate results when it is based on the corneal wavefront aberrations rather than on the corneal topography of the principal meridians. The wavefront guided profiles also allow customization of the ablation profiles to minimize the tissue ablation specially critical in keratoconic cases. The use of corneal wavefront based ablation on irregular corneal surface for these keratoconic patients could be argued, however, we favored corneal wavefront based profiles mainly due to their theoretical advantages over topography based profiles, namely customizability, tissue saving, same optical origin (as corneal topography), best attainable CDVA and the best attainable topographic regularization.

In our series, notably only two eyes (5%) needed a secondary laser retreatment for the improvement of post-operative visual acuity. These patients showed high hyperopic shift after the initial sequential treatment of CXL followed by TransPRK, and were treated with a secondary TransPRK treatment. The hyperopic shift could be attributed to excessive flattening of the cornea either post-CXL, post-TransPRK or a combination of both. These results are not reported here to maintain uniformity. Concerning defocus correction, 23 eyes (62%) were within 1.50D of attempted correction in spherical equivalent and the attempted versus achieved scattergram (Fig. 3) showed an intercept of -1.2213D consistent with the mean deviation from target of +1.09 ± 2.36D. These results may eventually be explained by the effects of CXL therapy on progressive corneal flattening, but also the potential effects of the CXLed tissue on ablation rate. Some groups have reported reduced ablation rate in CXL corneas opposed to our clinical findings. Another explanation could be that the flattening of the cornea is simply due to the conus ablation which may not be well computed by the programme as it is complex to forecast this data.

The mean residual astigmatism of 2.34 ± 1.81D can be explained by the fact that we did not attempt to

Figure 4  Deviation from target spherical equivalent refraction (SE) in keratoconic patients who underwent corneal collagen cross linking followed by Corneal-Wavefront guided transepithelial photorefractive keratectomy (TransPRK). Twenty two percent eyes were within −0.5D to +0.5D of SE deviation from the target. The mean deviation from target SE was +1.09 ± 2.36D (−2.50 to +7.38D) (paired t-test $P < .001$).
Correct the full astigmatism in most cases. The treatment was planned not to exceed the stromal ablation depth more than 55 μm (excessively not to reduce the strength of the cornea reinforced by the CXL therapy). Furthermore, the manifest refractive astigmatism may be influenced by HOA (especially coma and trefoil), however, the observed deviation from target astigmatism was much lower (0.64 ± 1.85D).

Generally, complete spherical and 50% astigmatic correction was targeted, but not in all cases. This decision primarily depended on the corneal thickness and the individual case. Hence, in order to avoid any confusion we analyzed achieved versus planned correction (and not manifest refraction). Although our results show significant reduction in coma and astigmatism, we cannot compare these extreme cases to the outcomes of refractive and transplant surgery in normal population. The aim of this surgery was to improve the CDVA enough to enable the use of conventional correction modalities like spectacles and increase the tolerance to contact lenses. UDVA improvement, although desirable, were only considered as secondary end point for the population in this study.

Although this small series of treated eyes does not allow for definitive conclusions or evidence-based statements, our

**Figure 5** Deviation from target Refractive astigmatism (Ast) in keratoconic patients who underwent corneal collagen cross linking followed by Corneal-Wavefront guided transepithelial photorefractive keratectomy (TransPRK). The mean deviation from target astigmatism was 0.64 ± 1.85D (−3.00 to +6.00D) (paired t-test P < .0001) with 38% eyes achieving <0.5D of astigmatic deviation from the target.

**Figure 6** Corneal wavefront (CW) high-order-aberrations (HOA) in keratoconic patients who underwent corneal collagen cross linking followed by Corneal-Wavefront guided transepithelial photorefractive keratectomy (TransPRK). Average coma aberration, average spherical aberration (SphAb) and root mean square (RMS) of HOA were 1.08 μm, −0.08 μm and 2.83 μm at the last follow visit, measured at 5 mm analysis diameter. Post-operatively average coma aberration reduced by −33 ± 81% and RMS of the HOA by −25 ± 32%.

**Figure 7** Preoperative versus postoperative higher order aberrations (HOA) measured at 5 mm analysis diameter in keratoconic patients who underwent corneal collagen cross linking followed by Corneal-Wavefront guided transepithelial photorefractive keratectomy (TransPRK). Coma aberrations, spherical aberrations (SphAb) and root mean square (RMS) of HOA were under-corrected by 73%, 35% and 33% respectively, at the last follow up visit.
preliminary results are promising. However, there are some limitations associated with our study, mainly the lack of a control group and shorter follow up times. Mean follow-up time of 10 months could be too short for the keratoconus population, where the topographically manifest ectatic process may show much later, after the limit of the epithelial compensatory ability has been reached. In our cohort, the mean age was 35 ± 12 years (19–64 years). The scientific evidence regarding the progression of keratoconus and efficacy of CXL with growing age might indicate against CXL treatments in older patients in our cohort. However, one cannot generalize that in all keratoconus patients the condition progresses similarly. In addition, in case of older patients presenting with abnormal corneas and willing to get their refractive aberrations corrected, it is imperative to reinforce the stroma before commencing any refractive procedure. However, it must be acknowledged that the efficacy of CXL treatments might be affected by the age of the patient, and a surgeon must consider the stability in the cornea after CXL before performing any refractive procedure.

It could also be argued whether the cornea is stable enough to perform a transepithelial PRK only 4 months after CXL. One can observe changes in the cornea in some patients, even after 7 years post a CXL procedure. In our cohort, a minimum follow up of at least four months after CXL was chosen since it was clinically observed that in general topographies become stable at least four months after conventional CXL in keratoconus patients. Furthermore, whether the cornea continues to flatten becomes less important for the results of our study, since the primary outcome in our cohort was CDVA and not UDVA, aimed at improving the patient’s vision with the use of conventional correction modalities like spectacles and increasing tolerance to contact lenses.

The choice between simultaneous and sequential refracto-therapeutic treatments has been debated in the past. Simultaneous refracto-therapeutic treatments involve a same day procedure with a customized refractive treatment followed by a CXL treatment to control the progression of keratoconus. However, changes in the shape of cornea post CXL, may further manipulate the intended refractive correction. In order to avoid such an occurrence, in our cohort the refractive procedure was performed at least four months after the cornea became stable post the CXL procedure, where the corneal stability was controlled with differential topographic maps. It is well known that the epithelial thickness varies greatly in keratoconus. Treating the standard thickness of 55 μm in the centre, increasing the depths towards the mid-periphery may be satisfactory for non-keratoconic eyes, but might lead to excessive removal of stromal tissue in the cone area, where the epithelial thickness normally is at its minimum (most often in the range of 40 rather than 60 μm). Although the CXL procedure shall improve the keratoconic symptoms in the cornea, the use of similar epithelial profiles might affect the keratoconic eyes adversely compared to non-keratoconic eyes. However, our results suggest improved corrected vision with 41% of eyes (15 eyes), gaining two or more Snellen lines of CDVA (paired t-test \(P < 0.0001\)) and only 5% losing 1 line (Fig. 2). Furthermore, there were no topographic or clinical signs of keratoconus progression during the follow-up period suggesting the safety of the procedure. Haze did not pose a problem in our cohort thanks to the use of MMC with only 5 cases (13%, with traces up to grade 1) showing this problem in our analysis.

It is necessary to emphasize the compromise between the use of large optical zones, covering the scotopic pupil size (plus some tolerance for possible decentrations), and smooth transition zones. In our study, this compromise was realized by using a mean optical zone of 6.1 ± 0.3 mm (range 5.5–6.7 mm), fully corrected central ablation zone with a multidynamic aspherical transition zone automatically provided by the laser based on the planned refractive correction (6.8 ± 0.5 mm, range 6.2–8.1 mm).

Refracto-therapeutic procedures have been conducted with different strategies in the past. The Athens protocol evaluated a series of 32 cases with corneal ectasia after LASIK that underwent combined topography-guided PRK to reduce or eliminate induced myopia and astigmatism followed by sequential, same-day ultraviolet A (UDVA) CXL. Twenty-seven of 32 eyes had an improvement in UDVA and CDVA of 20/45 or better (2.25 logMAR) at last follow-up and corneal haze grade 2 was present in 2 eyes. Seventeen of 32 eyes showed improvements in UDVA and CDVA with a follow-up longer than 1.5 years. Although the comparability between our setting (naturally occurring keratoconic ectasia) and Kanellopoulos (LASIK induced iatrogenic keratectasia) may be limited, our series reports 37 eyes, with an improvement in UDVA and CDVA of 20/40 or better (+0.35 logMAR) at last follow-up, with 30 eyes showing topographic improvement, whereas 2 of the treated eyes requiring a secondary transepithelial ablation.

Some reports do advocate for simultaneous CXL concurrent with refractive correction as compared to sequential CXL therapy followed by refractive correction (as in our case). Kanellopoulos et al. studied a total of 325 eyes with keratoconus divided into two groups (n = 127 eyes for the sequential group, and n = 198 eyes for the simultaneous group). At the last follow-up in the sequential group, the mean UDVA improved to 0.49 ± 0.25 logMAR, and the mean CDVA improved to 0.16 ± 0.22 logMAR. Mean reduction in spherical equivalent refraction was 2.50 ± 1.20D and mean hase score was 1.2 ± 0.5. In the simultaneous group, the mean UDVA improved to 0.3 ± 0.2 logMAR, and the mean CDVA improved to 0.11 ± 0.16 logMAR. Mean reduction in spherical equivalent refraction was 3.20 ± 1.40D and mean hase score was 0.5 ± 0.3. Statistically, the simultaneous group did better (\(P < 0.05\)) in all fields evaluated, with improvement in UDVA and CDVA, a greater mean reduction in spherical equivalent refraction, keratometry, and less corneal haze. Compared to this study, our smaller sample sized sequential setting showed that the mean UDVA improved from 1.0 ± 0.6 logMAR to +0.4 ± 0.4 logMAR, and mean CDVA improved from +0.4 ± 0.2 logMAR to +0.2 ± 0.2 logMAR at the last follow-up. Mean reduction in spherical equivalent refraction was −1.09 ± 2.36D, and mean hase score was 0.1 ± 0.2.

Kymionis et al. compared the outcomes of corneal collagen cross-linking (CXL) for the treatment of progressive keratoconus using transepithelial PTK (t-PTK) versus mechanical epithelial debridement. In group 1 (t-PTK), log-alrithm of the minimum angle of resolution mean UDVA and mean CDVA improved from 0.99 ± 0.71 and 0.30 ± 0.26
Corneal-Wavefront guided transepithelial photorefractive keratectomy

preoperatively to 0.63 ± 0.42 (P = 0.02) and 0.19 ± 0.18 (P = 0.008) at 12 months postoperatively, respectively. In group 2 (mechanical debridement), neither mean UDVA nor mean CDVA demonstrated a significant improvement at 12 months postoperatively (P > 0.05). In group 1, mean corneal astigmatism improved from −5.84 ± 3.80 diopters (D) preoperatively to −4.31 ± 2.90D (P = 0.015) at the last follow-up, whereas in group 2 there was no significant difference at the same postoperative interval (P > 0.05). They concluded that epithelial removal using t-PTK during CXL results in better visual and refractive outcomes in comparison with mechanical epithelial debridement.

A recent report suggests that non-topographic transepithelial PRK with simultaneous crosslinking improves vision, and may offer an alternative to keratoplasty in contact lens intolerant keratoconus. The most notable finding of this series was a significant improvement in vision, both corrected and unaided. The proportion of eyes achieving a functional threshold of 0.1 logMAR (Snellen 6/8.5) increased from 22 to 64%, a significant proportion who might otherwise have to consider keratoplasty. Notably, even in cases with residual refractive errors, these were easily correctable with glasses or soft contact lenses rather than rigid lenses, with benefits in wear time and tolerance. These visual acuity improvements compare favourably to those described in published series of topographically guided excimer treatments. By comparison, current studies of CXL alone demonstrate a modest and unpredictable improvement in visual function in just over half of the cases, with the remainder remaining stable, but a proportion also worsening in terms of visual acuity. Also in this series, correction of topographic parameters was not directly targeted by the technique; however, there was a significant improvement in topographic parameters.

Further analysis of the postoperative night vision complaints and the analysis of post-operative outcomes according to optical zone size are also of interest. Long-term follow-up on these eyes will help determine whether these results also show improved stability over time. We are aware that a laser treatment on an unstable cornea could lead to a dehiscence in future but one must weigh the advantage of a fast and easy procedure with improved visual quality to the possible variation (but not certain risk) of astigmatism in the future.

The reduction of preoperative astigmatism to moderate values postoperatively, with significant reduction in HOA in our cohort suggests that reversed single-step Corneal-Wavefront guided transepithelial PRK ablation profiles with AMARIS yield good visual, optical, and refractive results for the correction of refracto-therapeutic problems in keratoconic patients.

Funding

None.

Contributors

Camellin concept, performing the treatments, reviewing the article. Guidotti concept, reviewing the article. Arba Mosquera writing the article, providing statistical expertise.

Conflicts of interest

Arba Mosquera is employee of SCHWIND eye tech solutions manufactur of the SCHWIND AMARIS used in this study.

References